Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators

Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators

The goal of this clinical trial is to evaluate a community pharmacist intervention aimed at improving medication adherence in patients starting newly prescribed medication for cardiovascular disease prevention. The main questions it aims to answer are:

• Does this community pharmacist intervention improve medication adherence?
• Which patients benefit the most from the intervention?
• How do patients experience the start-up of newly prescribed medication (which questions do they have and do they experience side effects?)?
• How do patients and pharmacists experience the intervention?

Inclusion Criteria:

• Patients presenting with a first prescription for one of the following drug classes: antihypertensive drugs (= low-ceiling diuretics, beta blocking agents (excl. non-selective beta-blocking agents), ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers), lipid-lowering drugs (= statins), antidiabetic drugs (= metformin, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose co-transporter 2 (SGLT2) inhibitors), or any combination thereof.
• Age 18 years or older
• Community-dwelling

Exclusion Criteria:

• The drug is prescribed for a non-cardiovascular indication (e.g. beta-blocking agent for migraine prophylaxis)
• Communication with the patient is not possible (e.g. due to cognitive impairment, insufficient knowledge of Dutch or French language)